VAUGHAN, Ontario–( )–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U. S. introduction of PreserVision ® AREDS 2 Formula mini soft gels with OCUSorb . This product is the only AREDS 2 eye vitamin with the OCUSorb formulation. Offering a proprietary composition associated with lutein and zeaxanthin, OCUSorb has been clinically shown to provide superior absorption of these nutrients into the body as compared to the particular original PreserVision AREDS two mini smooth gel formula. † 1 *

For my patients with moderate to advanced Age-related Macular Degeneration (AMD), a top cause of vision loss in Americans ages 50 plus older, I typically recommend a plan that includes a healthy diet, exercise and PreserVision ® AREDS 2 Method eye vitamins to help reduce the risk of disease progression, ” said Rishi Singh, M. D., staff physician and president, Cleveland Clinic Martin Hospitals, Stuart, Fla. “ Now using the OCUSorb method, lutein plus zeaxanthin are better absorbed in the body, helping to increase the particular amount of nutrition that can circulate to patient’s eyes. I am pleased to recommend this new enhanced formula to my patients. ”‡*

PreserVision ® AREDS 2 Formulation eye nutritional vitamins, including the new OCUSorb formula, contain the exact nutrient formulation recommended by the National Eye Institute (NEI). This precise formula includes certain amounts of lutein and zeaxanthin, which are two important antioxidants that have been clinically shown through decades of research to assist reduce the chance of AMD development. In 2022, the NEI’s AREDS2 10-Year Follow-on Study further confirmed the benefits of lutein and zeaxanthin in the particular AREDS 2 formula. two

We’re pleased to offer eye care professionals plus their individuals this improved offering — the proven AREDS 2 formula vision vitamin along with better absorbing nutrients from the patented OCUSorb technology, ”* said Joe Gordon, chief executive, Global Consumer, Surgical and Vision Care, Bausch + Lomb. “ We remain committed to supporting plus providing the nearly 16 million Americans affected by AMD with products that will address their eye health needs. ”

PreserVision AREDS 2 Formula mini gentle gels along with OCUSorb are usually now available at most major retailers nationwide in the particular vitamin aisle or online and will replace the current PreserVision AREDS 2 Method mini gel formula. For more information on PreserVision eye vitamins, visit www.preservision.com .

About AMD

AMD is a progressive attention condition that impacts central vision and is a leading cause of blindness inside adults 50 years associated with age and older. Early-stage AMD often does not present any symptoms or changes in vision, as symptoms usually appear gradually over time. This progressive condition can impact one or both eyes, causing people in order to have difficulty with daily activities like driving, reading or recognizing the faces of loved ones. 3

About PreserVision ® AREDS 2 Formulation Eye Vitamins

PreserVision ® AREDS two formula eyesight vitamins, the most studied eyes vitamin brand, contain the exact NEI-recommended formula based on the particular AREDS2 study. The daily dose (two capsules) of PreserVision ® AREDS 2 nutritional vitamins provides the specific same levels of all six clinically confirmed nutrients as the NEI supported formula: supplement C (500mg), vitamin E (400 IU/180mg), lutein (10mg), zeaxanthin (2mg), zinc (80mg zinc oxide), and copper (2mg cupric oxide). With regard to more information on PreserVision ® , visit www.preservision.com .

Regarding the AREDS, AREDS2 plus 10-Year Follow-on AREDS2 Research Results

The AREDS and AREDS2 studies are landmark clinical studies conducted over 20 years by the NEI. The AREDS research in 2001 demonstrated that will taking a specific combination of antioxidants and zinc could help reduce the risk of progression of ADVANCED MICRO DEVICES in those with moderate to advanced AMD. In 2012, the NEI completed the particular AREDS2 study, which tested several changes to the formulation, such as adding omega-3 fatty acids, substituting lutein and zeaxanthin for beta-carotene, and/or reducing zinc. The current AREDS2 nutrient formula recommended from the NEI is the result of this particular study.

The particular NEI 10-Year Follow-on Study results evaluated the long-term results associated with participants who were involved in the AREDS2 research. Consisting of 3, 883 people (6, 351 study eyes) along with moderate in order to advanced ADVANCED MICRO DEVICES over a 10-year period, the follow-on research further validates the original findings of the AREDS2 formulation with lutein plus zeaxanthin, demonstrating an incremental reduction in danger from the development to late-stage AMD. 2

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of individuals around the world – from the moment associated with birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care items, eye treatment products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices plus instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12, 000 employees and the presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario along with corporate offices in Bridgewater, New Jersey. Regarding more info, visit www.bausch.com and connect with us on Twitter , LinkedIn , Facebook and Instagram .

Forward-looking Statements

This particular news release may consist of forward-looking statements, which may generally be identified by the use of the particular words “anticipates, ” “hopes, ” “expects, ” “intends, ” “plans, ” “should, ” “could, ” “would, ” “may, ” “believes, ” “estimates, ” “potential, ” “target, ” or even “continue” plus variations or similar expressions. These statements are based upon the present expectations and beliefs associated with management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks plus uncertainties include, but are usually not limited to, the dangers and questions discussed inside Bausch + Lomb’s filings with all the U. S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein simply by reference. They also include, but are not really restricted to, risks and uncertainties caused by or even relating to the evolving COVID-19 pandemic, plus the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain plus cannot be predicted, and which might have a material adverse impact on Bausch + Lomb, including but not limited to the project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any kind of these forward-looking claims. These forward-looking statements speak only because of the particular date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date associated with this news release or in order to reflect real outcomes, unless required by law.

*This statement has not been evaluated with the Food plus Drug Administration. This product is not really intended to diagnose, treat, cure or prevent any disease.

Compared to the market sample, at p< 0. 05.

‡Compared to original lutein and zeaxanthin in PreserVision AREDS two.

References

  1. Kotagiri SR, Morde A, Rai D, et al. Ophthalmol Ther. 2022; 11(4): 1463-1477.
  2. Chew EY, Clemons TE, Agrón Electronic, et al. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids towards the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmology. 2022; 140(7): 692–698. doi: 10. 1001/jamaophthalmol. 2022. 1640.
  3. National Vision Institute Website. Retrieved through https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration . Accessed Dec. 14, 2022.

PreserVision is a trademark of Bausch & Lomb Incorporated or its affiliates.

AREDS plus AREDS2 are registered trademarks of the particular United States Department associated with Health and Human Services (HHS).

Any other product/brand names are usually trademarks of the respective owners.

© 2023 Bausch & Lomb Incorporated or its affiliates.

PV2. 0152. USA. 22

Leave a Reply

Your email address will not be published. Required fields are marked *